Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Jefferies Group cut their FY2017 earnings estimates for Zimmer Biomet Holdings in a research note issued to investors on Wednesday. Jefferies Group analyst R. Denhoy now expects that the medical equipment provider will earn $8.03 per share for the year, down from their previous estimate of $8.24. Jefferies Group also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.10 EPS, Q1 2018 earnings at $2.04 EPS, Q2 2018 earnings at $2.02 EPS, Q3 2018 earnings at $1.94 EPS, Q4 2018 earnings at $2.25 EPS and FY2018 earnings at $8.25 EPS.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.79 EPS. TRADEMARK VIOLATION NOTICE: “FY2017 EPS Estimates for Zimmer Biomet Holdings, Inc. Reduced by Jefferies Group (ZBH)” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/02/fy2017-eps-estimates-for-zimmer-biomet-holdings-inc-reduced-by-jefferies-group-zbh.html.

Other equities analysts also recently issued research reports about the company. Guggenheim upgraded Zimmer Biomet Holdings from a “neutral” rating to a “buy” rating and set a $157.00 price objective for the company in a report on Wednesday, July 12th. BMO Capital Markets reiterated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Canaccord Genuity reiterated a “buy” rating and issued a $141.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Bank of America Corporation reiterated a “buy” rating and issued a $158.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $141.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings presently has a consensus rating of “Hold” and a consensus target price of $136.55.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. increased its holdings in Zimmer Biomet Holdings by 8.1% in the 3rd quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock worth $487,721,000 after buying an additional 311,654 shares in the last quarter. Gabelli Funds LLC increased its holdings in Zimmer Biomet Holdings by 36.3% in the 3rd quarter. Gabelli Funds LLC now owns 192,300 shares of the medical equipment provider’s stock worth $22,516,000 after buying an additional 51,200 shares in the last quarter. Gamco Investors INC. ET AL increased its holdings in Zimmer Biomet Holdings by 55.3% in the 3rd quarter. Gamco Investors INC. ET AL now owns 485,919 shares of the medical equipment provider’s stock worth $56,896,000 after buying an additional 173,076 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its holdings in Zimmer Biomet Holdings by 2.2% in the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 33,218 shares of the medical equipment provider’s stock worth $3,889,000 after buying an additional 700 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Zimmer Biomet Holdings by 5.1% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 30,295 shares of the medical equipment provider’s stock worth $3,547,000 after buying an additional 1,469 shares in the last quarter. Institutional investors own 85.26% of the company’s stock.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Investors of record on Friday, September 22nd were issued a $0.24 dividend. The ex-dividend date of this dividend was Thursday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet Holdings’s payout ratio is 27.59%.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.